Results 231 to 240 of about 45,838 (288)

System level network data and models attack cancer drug resistance

open access: yesBritish Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély   +6 more
wiley   +1 more source

Targeting hexokinase 2 to induce breast cancer cell senescence

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof   +8 more
wiley   +1 more source

Radiomics-Based Detection of Germ Cell Neoplasia In Situ Using Volumetric ADC and FA Histogram Features: A Retrospective Study. [PDF]

open access: yesCancers (Basel)
Christodoulou MV   +7 more
europepmc   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich   +7 more
wiley   +1 more source

Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types. [PDF]

open access: yesBMC Cancer
Büyücek S   +27 more
europepmc   +1 more source

EMB‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy

open access: yesCancer Science, EarlyView.
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Jing Gao   +9 more
wiley   +1 more source

Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer

open access: yesCancer Science, EarlyView.
YAP/TAZ, key effectors in lung cancer progression, paradoxically sensitize tumor cells to ferroptosis. This study reveals that YAP/TAZ‐low cells confer non‐cell‐autonomous, GCH1‐mediated durable ferroptosis resistance to neighboring YAP/TAZ‐high cells via a soluble factor, highlighting a Hippo pathway‐linked mechanism of tumor adaptation and survival ...
Mohamed Fathi Saleh   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy